



# SUCCESSFUL \$15 MILLION PLACEMENT AND ANNOUNCEMENT OF SHARE PURCHASE PLAN

## Highlights

- Tetratherix Limited (ASX:TTX) (**Tetratherix**) has received firm commitments from new and existing institutional investors for a Placement to raise \$15M (before costs) (**Placement**).
- The Placement was conducted at \$6 per share, a 2% discount to the 10-day VWAP.
- SPP offer to be made to existing eligible shareholders to raise up to a further \$2M.
- Proceeds from the Placement and SPP will be used to fund production expansion, strategic partnerships, customer success, digitalisation, working capital and transaction costs.

## Will Knox CEO commented:

"This \$15 million capital injection, backed by exceptional demand from both existing and new institutional partners, is a definitive validation of Tetratherix's technical, commercial and organisational advantages. The market has recognised the compounding value of our Tetramatrix™ polymer platform, attracting world class investors. We are scaling a highly integrated, increasingly digitalised, and fundamentally unique medical technology platform.

This capital further secures a fully funded, exciting runway as we rapidly transition to commercialisation in 2026. It allows us to immediately supercharge our production mechanics, expand our strategic partnership ecosystem, and embed comprehensive customer success infrastructure to capture global market share with our partners. Over the past 12 months, our industry leading team has demonstrated relentless operational execution by consistently hitting our commercial, clinical and development milestones. We enter this next chapter with immense momentum as we aggressively commercialise our platform to deliver value."

## Details of the Placement

The Placement to sophisticated and professional investors will raise gross proceeds of \$15M from a two-tranche issue of new fully paid ordinary shares (**Placement Shares**). The issue price of \$6 represents a 2% discount to the 10-day Volume Weighted Average Price (**VWAP**) of \$6.12. Placement Shares will rank equally with existing shares of Tetratherix from their issue date. Placement Tranche 1 shares, shares issued to new and existing institutional investors, are anticipated to settle on 3 June 2026. Placement Tranche 2 shares, shares issued to Directors (or nominees) of Tetratherix, are subject to shareholder approval at a general meeting of shareholders.

## Details of the Share Purchase Plan

Tetratherix will also offer eligible shareholders the opportunity to participate in a non-underwritten share purchase plan (**SPP**) to raise up to a further \$2M (before costs). Under the SPP, eligible TTX shareholders, being shareholders with registered addresses in Australia or New Zealand on TTX's register as at 7:00pm (Sydney time) on 26 May 2026, being the record date (**Eligible Shareholders**), can apply for up to \$30,000 worth of new fully paid ordinary shares in the Company (**SPP Shares**) without incurring brokerage or other transaction costs.

The SPP Shares will be issued at \$6, being the amount to be paid by institutional investors under the Placement.

The SPP offer period will be open on 4 June 2026 and is expected to close at 5:00pm (Sydney time) on 18 June 2026 (unless extended or closed earlier at the discretion of Tetratherix).

**ASX RELEASE**

28TH MAY 2026



### **Details of the Share Purchase Plan Continued**

Further details of the SPP will be set out in the SPP Offer Booklet, which will be released to the ASX and made available to eligible shareholders in Australia and New Zealand on or around 4 June 2026.

Given the SPP is capped at \$2M, in the event of oversubscription, Tetratherix will scale back applications. Any scale back will be applied on a pro rata basis, having regard to the applicant's shareholding at the record date and will be conducted having regard to all applicable regulatory requirements.

### **Placement and SPP Investor Presentation**

Please see the investor presentation **attached** to this announcement.

### **Joint Lead Managers**

Barrenjoey Markets Pty Limited and Morgans Corporate Limited acted as joint lead managers to the Placement.

**< ENDS >**

This announcement was authorised for ASX release by the CEO.

For further information please contact:

#### **Jacob Pfeffer**

General Counsel | Company Secretary

+61 425 194 200

[jacob.pfeffer@tetratherix.com](mailto:jacob.pfeffer@tetratherix.com)

<https://tetratherix.com/>

ASX: TTX

May 2026

# Tetratherix Growth Capital Presentation

## Important Information & Disclaimer



This investor presentation (**Presentation**) is dated 26 May 2026 and has been prepared by Tetratherix Limited ACN 607 771 077 (**Tetratherix** or **Company**). By attending an investor presentation or briefing, or accepting, accessing or reviewing this Presentation, you acknowledge and agree to the terms set out below. This Presentation has been prepared in relation to: (i) a placement of fully paid ordinary shares in Tetratherix (**New Shares**) to institutional investors under section 708A of Corporations Act as modified by ASIC Corporations (Disregarding Technical Relief) Instrument 2016/73 (**Placement**); and (ii) a share purchase plan in accordance with ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 (**SPP**), (the Placement and SPP together, the **Offer**).

### Summary information

This Presentation is for information purposes only and is a summary only. It should be read in conjunction with Tetratherix's most recent financial report and Tetratherix's other periodic and continuous disclosure information lodged with the Australian Securities Exchange (**ASX**), which are available at [www.asx.com.au](http://www.asx.com.au). The content of this Presentation is provided as at the date of this Presentation (unless otherwise stated). Reliance should not be placed on information or opinions contained in this Presentation and, subject only to any legal obligation to do so, Tetratherix does not have any obligation to correct or update the content of this Presentation.

Certain market and industry data used in this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Tetratherix nor its representatives have independently verified any such market or industry data provided by third parties or industry or general publications.

### Not financial product advice or offer

This Presentation does not, and does not purport to, contain all information necessary to make an investment decision, is not intended as investment or financial product advice (nor tax, accounting or legal advice), must not be relied upon as such and does not and will not form any part of any contract or commitment for the acquisition of New shares. Any decision to buy or sell securities or other products should be made only after seeking appropriate financial advice.

This Presentation is of a general nature and does not take into consideration the investment objectives, financial situation or particular needs of any particular investor.

Any investment decision should be made solely on the basis of your own enquiries. Before making an investment in Tetratherix, you should consider whether such an investment is appropriate to your particular investment objectives, financial situation or needs. Tetratherix is not licensed to provide financial product advice in respect of its shares.

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law or any other law (and will not be lodged with the Australian Securities and Investments Commission (**ASIC**) or any other foreign regulator). This Presentation is not, and does not constitute, an invitation or offer of securities for subscription, purchase or sale in any jurisdiction.

The distribution of this Presentation in jurisdictions outside Australia is restricted by law and you should observe any such restrictions, including those set forth in Appendix C of this Presentation. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. Refer to Appendix C of this Presentation for further details about international offer restrictions.

This Presentation may not be distributed or released in the United States. The entitlements and the New shares have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (U.S. Securities Act), or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold, directly or indirectly, in the United States, unless they have been registered under the U.S. Securities Act (which Tetratherix has no obligation to do or procure) or are offered or sold in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable U.S. state securities laws.

The SPP booklet for the SPP will be available following its lodgement with ASX. Any eligible retail shareholder in Australia or New Zealand who wishes to participate in the SPP should consider the SPP booklet before deciding whether to apply under that offer.

### Investment risk

An investment in Tetratherix shares is subject to known and unknown risks, some of which are beyond the control of Tetratherix and its directors. Tetratherix does not guarantee any particular rate of return or the performance of Tetratherix, nor does it guarantee any particular tax treatment. You should have regard to the risk factors outlined in Appendix B of this Presentation when making your investment decision. Cooling off rights do not apply to the acquisition of New shares.

### Financial information

All financial information in this Presentation is in Australian dollars (\$) or (\$) unless otherwise stated. This Presentation may contain certain pro forma financial information. Any such pro forma financial information provided in this Presentation is for illustrative purposes only and is not represented as being indicative of Tetratherix's views on its, nor anyone else's, future financial position and/or performance. Any pro forma financial information has been prepared by Tetratherix in accordance with the measurement and recognition principles, but not the disclosure requirements, prescribed by the Australian Accounting Standards (**AAS**). In addition, the pro forma financial information in this Presentation does not purport to be in compliance with Article 11 of Regulation S-X of the rules and regulations of the U.S. Securities and Exchange Commission, and such information does not purport to comply with Article 3-05 of Regulation S-X.

Investors should be aware that certain financial measures included in this Presentation are 'non-IFRS financial information' under ASIC Regulatory Guide 230: 'Disclosing non-IFRS financial information' published by ASIC and also 'non-GAAP financial measures' within the meaning of Regulation G under the U.S. Securities Exchange Act of 1934, as amended, and are not recognised under AAS and International Financial Reporting Standards (**IFRS**). Such non-IFRS financial information/non-GAAP financial measures do not have a standardised meaning prescribed by AAS or IFRS. Therefore, the non-IFRS financial information may not be comparable to similarly titled measures presented by other entities and should not be construed as an alternative to other financial measures determined in accordance with AAS or IFRS. Although Tetratherix believes these non-IFRS financial measures provide useful information to investors in measuring the financial performance and condition of its business, investors are cautioned not to place undue reliance on any non-IFRS financial information/non-GAAP financial measures included in this Presentation.

Certain figures, amounts, percentages, estimates, calculations of value and fractions provided in this Presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this Presentation.

### Past performance

Past performance, including past share price performance of Tetratherix and pro forma financial information given in this Presentation, is given for illustrative purposes only and should not be relied upon as (and is not) an indication of Tetratherix's views on its future financial performance or condition. Past performance of Tetratherix cannot be relied upon as an indicator of (and provides no guidance as to) the future performance of Tetratherix. Nothing contained in this Presentation nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past, present or future.

### Future performance and forward-looking statements

This Presentation contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of Tetratherix, its directors and management. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

You are strongly cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic climate and geopolitical tensions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of Tetratherix's business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of Tetratherix, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation. The forward-looking statements are based on information available to Tetratherix as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing Rules), none of Tetratherix, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

### Disclaimer

Barrenjoey Markets Pty Limited ABN 66 636 976 059 (**Barrenjoey**) and Morgans Corporate Limited (ABN 32 010 539 607) (**Morgans**) are acting as joint lead managers (**JLMs**) to the Placement. Each JLM and each of their respective related bodies corporate, shareholders or affiliates and their respective officers, directors, employees, affiliates, agents or advisers have not authorised, permitted or caused the issue, lodgement, submission, dispatch or provision of this Presentation and do not make or purport to make any statement in this Presentation and there is no statement in this Presentation which is based on any statement by such persons. You agree that you have not relied on any statement made by such persons in relation to the Offer and you further expressly disclaim that you are in a fiduciary relationship with any of them in relation to the Offer. To the maximum extent permitted by law, Tetratherix, each of the JLMs and each of their respective related bodies corporate and affiliates, and their respective officers, directors, employees, agents and advisers:

(i) disclaim all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation, and have not independently verified such information and take no responsibility for any part of this Presentation or the Offer; (ii) disclaim any obligations or undertaking to release any updates or revisions to the information in this Presentation to reflect any change in expectations or assumptions; and (iii) do not make any representation or warranty, express or implied, as to the accuracy, reliability, completeness of the information in this Presentation or that this Presentation contains all material information about Tetratherix or that a prospective investor or purchaser may require in evaluating a possible investment in Tetratherix or acquisition of shares in Tetratherix, or likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement. You acknowledge and agree that determination of eligibility of investors for the purposes of the Offer is determined by reference to a number of matters, including legal requirements, logistical and registry constraints and the discretion of Tetratherix and the JLMs. Each of Tetratherix and the JLMs disclaim any duty or liability (including for negligence) in respect of the determination, exercise or otherwise of that discretion, to the maximum extent permitted by law. Tetratherix and the JLMs (and their respective affiliates) may rely on information provided by and on behalf of investors in connection with managing and conducting the Offer and without having independently verified that information, and do not assume any responsibility for the accuracy or completeness of that information. Each of the JLMs and their affiliates are full service financial institutions engaged in various activities, which may include trading, financial advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non-financial activities and services including for which they have received or may receive customary fees and expenses or other transaction consideration. In the course of these activities, each of the JLMs and their affiliates may at any time for their own account and for the accounts of their clients make or hold investments in equity securities or other financial products of Tetratherix or its affiliates and receive customary fees and expenses or other transaction consideration in respect of such activities. The JLMs have received or expect to receive fees and reimbursement of expenses. This presentation is for corporate communication purposes only and is not intended as promotion or advertising to any audience in any jurisdiction. This presentation may also contain statistical data and information based on independent sources, industry publications or other publicly available information. We have not independently verified the accuracy or completeness of such data and information. Accordingly, we make no representations as to the accuracy or completeness of such data or information. You are cautioned not to give undue weight to such data.

# Executive Summary

---

- Tetramatrix™ is the Tetratherix proprietary biomaterial platform utilised across three established franchises - bone regeneration, tissue spacing and tissue healing - underpinned by a capital-light licensing and supply model
- Core franchises remain on track and in line with the timelines outlined in the prospectus. Our Tegenix (dental) FDA 510k process remaining on track with all TTX testing and reporting completed, submission and review process is well underway. TTX has one final third party report to submit upon receipt in the coming weeks. Depending on FDA review timelines, this review could be complete as early as July but the company has no clarity on exact timelines
- In March 2026, Tetratherix announced a fourth franchise - Precision Medicine - anchored initially on an exclusive R&D agreement with US precision health company Superpower Health Inc, which will pay Tetratherix US\$3m per annum in licence fees plus additional polymer sales revenue for up to 10 years, making the new franchise immediately revenue-generating in FY26. Tetratherix has received the cash payment for the first year licencing fee and the first polymer sale is imminent
- Critically, the Precision Medicine franchise is entirely additive - it leverages the same Tetramatrix™ platform polymer (branded as STEPP) as the existing franchises and has been developed in stealth over 5 years partially in collaboration with big-pharma leaders
- Nine months post-IPO Tetratherix has delivered against key prospectus milestones on time and on budget, with a strong cash position of A\$19.2m as at 31 March 2026 - funds raised at the IPO have been deployed as disclosed in the prospectus - Tetratherix is funded through to the start of FY28
- Tetratherix is today announcing an equity raising to raise A\$15m to fund incremental growth over and above the IPO strategic plan, the raise represents the accelerated evolution of Tetratherix from an R&D entity to a commercial organisation

## Why does the world need Tetratherix?

The evolving dynamics of the global healthcare system are demanding innovative and cost-effective biomaterials

### Trends in healthcare delivery



#### Rising patient expectations

Patients are increasingly demanding higher quality of care with a particular focus on **reducing recovery times** and **lower risk of complications** (e.g. infection, blood loss, pain) - which is also a driver of increasing healthcare costs for patients and payers



#### Need for cost-effective, decentralised care

Increasing global healthcare spending and demand for healthcare services is necessitating investment in **cost-effective tools and treatments**, including those that can be **delivered outside a traditional hospital setting**, to minimise burden on the healthcare system

# 70m

Estimated 70 million US outpatient procedures per year and increasing by >6%

# 60%

Nearly 60% of outpatients are operated on in ASCs

# 2X

These numbers are forecast to double over the next 10 years



Orthopaedic, ophthalmology, urology and neuro/pain are the main segments being disrupted

## How does Tetramatrix™ help facilitate this shift?

Our Tetramatrix™ platform is best positioned to address the clinical demands that are central to the evolution



### Minimally invasive delivery

Water-based solution injected through fine gauge needle



### Seamlessly integrated into existing workflows

No additional equipment required

## Tetramatrix™



### Safe, biocompatible and bioresorbable

No foreign body reaction upon application



### Low cost, scalable production


Non-labour intensive, low cost and readily available materials

# Tetramatrix™ platform technology is the world's first biostealth fluid matrix

## Intelligent




A **decade of polymer programming** has led to an ideal consistency & physical performance. The material is an **injectable fluid** to avoid causing damage to the body during its application. Using physiological temperature, material transitions into a 3D matrix.



## Modular



A biomaterial platform built with unique polymer programming **akin to “medical Lego®”** to form implantable products to solve a wide range of clinical problems. The platform has built products for 7 anatomical sites with 3 chemical entities derived from the core technology.



## Biomimetic




The matrix has **similar water content and mechanical properties** to natural tissue, and therefore is **impervious to the body**, helping heal injuries or physically manipulating the body during surgical interventions.


### Human Histological Evaluation

- Inflammatory Fibrovascular (IFV)
- Tissue ingrowth

Standard of care



Treated with our platform



## Safe





Due to the **unique polymer programming of the material**, once the matrix serves its purpose, the material **gradually and safely bioresorbs** in the body with no impact locally or systemically. Biocompatibility data from multiple clinical trials show no impact to internal organs or blood markers.

### Preclinical studies (equivalent to 5 litre product administration)

- ✓ No effects on blood markers for internal functions of liver, kidney and spleen
- ✓ Fully resorbed and excreted from the body

# Derived medical devices from the Tetramatrix™ platform technology span multiple large franchises and significant near-term commercial opportunities

## Expansion by Design: Transitioning from Three Pillars to a Four-Node Ecosystem




# Different clinical needs. Different market segments. Single Tetramatrix™ platform technology.

## Think of us like a software platform business...



The Tetramatrix biomaterial is our **core ‘platform’ technology**. We have completed the foundational safety, efficacy and manufacturing work which is transferable across different clinical applications of the platform.

We will **license the IP** in a specific field to a leader in the segment. These partners complete the “final 20%” to turn the application into a clinical product. We will then manufacture the product and supply at attractive unit economics to our industry leading partners who distribute it through their sales channels.

We will enjoy periodic milestone payments as well as a steady flow of income from product supply - a dual revenue source brings the best of both worlds.



## Our Partner Matrix - How We Choose



## A capital light model with compounding revenue

While we build our own production and R&D infrastructure, we avoid committing capital on establishing multiple sales & distribution networks by utilising the capabilities of our partners' established teams.


Importantly, we operate in unison with our partners. Our high margin revenue compounds over time by adding new partnerships and launching new products.

Similar to a 'build-to-buy' model, we partner differently to, and at earlier stages than, traditional medtech companies. Therefore, our return profile is different and not built on expectations of an eventual acquisition.



### This unique and attractive model is enabled by:




- A platform technology that allows parallel developments
- Advanced manufacturing with economies of scale
- Partnerships with leading players who are motivated to sell over a long time
- A patient & deliberate strategy



# An operational moat with IP Leadership built on a global R&D infrastructure. This sets us apart.



**Supported by complete IP coverage**  
 Patent stack with 36 granted patents from 9 families of patent, extending to 2044 & beyond and fully owned by Tetratherix



ASX: TTX

# Overview of the Equity Raising



# Summary of the Equity Raising

Offer size, structure and underwriting	<ul style="list-style-type: none"> <li>The Company is undertaking an institutional placement to raise A\$15m via the issue of ~2.5 million new fully paid ordinary shares (<b>New Shares</b>) utilising their placement capacity under ASX listing rule 7.1 (<b>Placement</b>) <ul style="list-style-type: none"> <li>Placement size represents approximately ~4.9% of the Company's existing ordinary shares on issue</li> </ul> </li> <li>In addition to the Placement, the Company will also be undertaking a share purchase plan to eligible shareholders to raise up to A\$2 million (<b>SPP</b>)</li> <li>The Placement and the SPP are not underwritten</li> </ul>
Placement pricing	<ul style="list-style-type: none"> <li>The Placement and SPP will be conducted at A\$6 per New Share (<b>Offer Price</b>), representing a: <ul style="list-style-type: none"> <li>14.0% discount to the last close price of A\$6.98 per New Share on 25 May 2026</li> <li>10.8% discount to the 5-day volume weighted average price of A\$6.72</li> </ul> </li> </ul>
Use of proceeds	<ul style="list-style-type: none"> <li>Proceeds will be used to scale manufacturing capacity, drive commercialisation through go-to-market partnerships and customer success, and accelerate digitalisation across R&amp;D and clinical programs</li> </ul>
Ranking	<ul style="list-style-type: none"> <li>New Shares issued under the Placement and SPP will rank equally with existing shares in the Company from their respective issue dates</li> </ul>
Share purchase plan	<ul style="list-style-type: none"> <li>Eligible shareholders of the Company with a registered address in Australia and New Zealand will be invited to apply for up to A\$30,000 of New Shares free of any brokerage, commission and transaction costs</li> <li>The SPP may raise up to A\$2m</li> <li>Tetratherix retains the right to scale back applications (in whole or in part) at its absolute discretion that may result in the SPP raising more or less than A\$2m</li> <li>An SPP Booklet containing further details about the SPP will be made available to eligible shareholders on 4 June 2026</li> </ul>
Syndicate	<ul style="list-style-type: none"> <li>Barrenjoey Markets Pty Limited ABN 66 636 976 059 (<b>Barrenjoey</b>) and Morgans Corporate Limited (ABN 32 010 539 607) (<b>Morgans</b>) are acting as joint lead managers (<b>JLMs</b>) to the Placement</li> </ul>

## \$15m capital to fund incremental growth above IPO strategic plan

A\$15m to fund incremental growth over and above the IPO strategic plan. This raise represents the accelerated evolution of Tetratherix from an R&D to a commercial organisation.

### Expand production capacity to meet added demand



- Additional manufacturing pods and headcount to support the accelerating demand for the platform

### Customer success team establishment



- Focus on dedicated resourcing to work with partners on demand planning, relationship management and pricing reviews - represents the accelerated evolution of Tetratherix from an R&D to a commercial organisation

### Digitalisation



- Ramp up of digital science resourcing to increase operational efficiency and optimise use cases across the platform

Uses of funds	A\$m
Production expansion	6.8
Customer success team	2.9
Strategic partnerships	1.7
Digitalisation	1.5
Working capital	1.0
Offer costs	1.1
<b>Total uses of funds</b>	<b>15.0</b>

Following the Placement (excluding any potential SPP proceeds), Tetratherix's pro forma liquidity as at 31 March 2026 is approximately \$A37.6m

# TTX Growth Projection - Expediting the Addition of Manufacturing Pods & Automation


Current activity on budget, additional A\$6.8m required as a result of recent commercial and technical validations

## Addition of new pods to meet the added demand (A\$4.8m)

- Increase in the number of synthesis pods from 1 to 5 with added equipment and processing units
- Increase of finished goods pods from 2 to 6 with added equipment and processing units
- Increase manufacturing FTE to meet the demand

## Automation of quality and operations (A\$2.0m)

- Incorporation of a machine learning to increase efficiency in QMS/ batch release and demand planning
- Automate the facility sanitisation to remove 2 days process shutdown per month



# TTX Growth Projection – Customer Success Team and Operation Digitalisation

Additive activities as a consequence of accelerated recent commercial validations for customer success and business evolution for operation digitalisation

## Customer Success Team (A\$2.9m)


### Direct engagement with US partners (Superpower, Henry Schein etc)

A small but effective team of customer success experts with a presence in both the US and AU to support partners in market, i.e. Henry Schein in clinics and during market seeding and Superpower to maximise commercial return for Tetratherix and to optimise operational execution to further facilitate growth.

### Drug delivery regulatory support

In parallel working with regulatory bodies to compile the requirements for the polymer as an excipient for drug delivery (US pharmacopeia requirements, FDA IV-DMF) to ensure long-term and sustainable US-Market presence

## Operational Digitalisation (A\$1.5m)



### Cost reduction and future-proofing the operation

With an initial focus on clinical trial management and other R&D, we will digitalise the internal operation of the business with the ultimate aim to drive efficiencies in R&D investment, product development and commercialisation

# TTX continues to evolve and plans to relentlessly execute into FY27 and beyond

	FY2026	Present	FY2027	H2FY2027
DENTAL	HENRY SCHEIN®	✓ Data read-out from the FDA study	FDA Clearance	First Final Product Dispatch to HS Market Seeding for Portfolio Expansion
ORTHOPAEDIC		✓ Data read-out from the FDA study	FDA Clearance	Supply and Licensing Agreement Execution First Final Product Dispatch to US Partner
ONCOLOGY	✓ FDA QSub/ Regulatory Pathway Defined	✓ Tutelix First In Human Cohort 1 Read-out	✓ Tutelix Pivotal Trial Initiation Australia	Portfolio Expansion IDE Approval from FDA for the US Arm of the Pivotal
OPHTHALMIC	✓ BioOptix Licensing Agreement	✓ Alcon	✓ US / AU Capital Raise Preclinical Data Read-out	Interim Technical Reporting with Alcon FDA Pre-submission & Regulatory Pathway
SURGICAL SITE MGMT	✓ Cohort 2 Commenced	✓ Year 1 Follow up for Cohort 1 results published	✓ Initiation Cohort 3 TetraDerm Cohort 3 Initiation (Major Surgeries)	Primary End-point Cohort 2 Year 1 Data-readout from Cohort 2
OPERATIONS	✓ IGP Grant	✓ New Facility Signed and ISO Surveillance	✓ Board Restructure MDSAP Stage 1 Audit	MDSAP Stage 2 Audit The New Site Head Quarter Opening
PRECISION MEDICINE		✓ superpower	✓ First License Revenue	First Polymer Dispatch (STEPP) STEPP Sale Revenue GLP-1 Data Point 1

# Deal Timetable

Event	Date (AEDT)
<b>Placement</b>	
Trading halt	26 May 2026
Placement bookbuild opens	26 May 2026
Announcement of outcome of the Placement	28 May 2026
Trading halt lifted – trading resumes on the ASX	28 May 2026
Settlement of New Shares issued under the Placement	3 Jun 2026
Allotment and normal trading of New Shares issued under the Placement	4 Jun 2026
<b>SPP</b>	
SPP record date	27 May 2026
SPP offer opens and SPP offer booklet dispatched	4 Jun 2026
SPP closes	18 Jun 2026
Announcement of result of SPP	22 Jun 2026
SPP issue and allotment date	23 Jun 2026
Normal trading of SPP shares	24 Jun 2026

The timetable above is indicative only and subject to change. The Company reserves the right to alter the dates above in its full discretion and without prior notice, subject to the ASX Listing Rules and the Corporations Act.

ASX: TTX




# Execution since the June 2025 IPO

# 9 months after ASX listing - Efficient use of Funds and Strong Cash Position

DENTAL	Henry Schein Supply & Licensing Agreement Execution	Data read-out from the FDA study	FDA Submission	FDA Clearance		
ORTHOPAEDIC	Master Partnership Agreement Execution	Supply and Licensing Agreement Execution	FDA Submission	FDA Clearance		
ONCOLOGY	FDA Pre-submission/Regulatory Pathway Defined	Tutelix First In Human Cohort 1 Read-out	Quality & Supply Agreement Execution	US/AU Capital Raise	Tutelix Primary End Point for Cohort 2	Pivotal Clinical Trial Initiation
OPHTHALMIC	BioOptix Licensing Agreement	Strategic Global Partnership	US / AU Capital Raise	Preclinical Data Read-out	FDA Pre-submission & Regulatory Pathway	
SURGICAL SITE MGMT	Cohort 2 Commenced	Year 1 Follow up for Cohort 1 results published	TetraDerm Cohort 3 Initiation (Major Surgeries)	FDA Pre-submission & Regulatory Pathway	Primary End-point Cohort 2	
OPERATIONS	IGP Grant	ISO13485 surveillance Audit	New Facility Signed and production begins	Board Restructure	MDSAP Stage 1 Audit	

FY26

FY27



# Commercial Milestones & Partnerships

DENTAL	Henry Schein Supply & Licensing Agreement Execution                  Data read-out from the FDA study                  FDA Submission                  FDA Clearance
ORTHOPAEDIC	Master Partnership Agreement Execution                  Supply and Licensing Agreement Execution                  FDA Submission                  FDA Clearance
ONCOLOGY	FDA Pre-submission/Regulatory Pathway Defined                  Tutelix First In Human Cohort 1 Read-out                  Quality & Supply Agreement Execution                  US/AU Capital Raise                  Tutelix Primary End Point for Cohort 2                  Pivotal Clinical Trial Initiation
OPHTHALMIC	BioOptix Licensing Agreement                  Strategic Global Partnership                  US / AU Capital Raise                  Preclinical Data Read-out                  FDA Pre-submission & Regulatory Pathway
SURGICAL SITE MGMT	Cohort 2 Commenced                  Year 1 Follow up for Cohort 1 results published                  TetraDerm Cohort 3 Initiation (Major Surgeries)                  FDA Pre-submission & Regulatory Pathway                  Primary End-point Cohort 2
OPERATIONS	IGP Grant                  ISO13485 surveillance Audit                  New Facility Signed and production begins                  Board Restructure                  MDSAP Stage 1 Audit

FY26

FY27

Global Distribution and Supply Agreement with the world's largest provider of healthcare solutions for dental market launch.



R&D agreement with the world's biggest ophthalmology technology company to develop next generation ophthalmic devices.



Tutelix successfully completed its Series A capital raise to expedite clinical trial and launch in the US - supported by US clinicians.



Tetratherix has announced a new US partnership in precision medicine with Superpower Health.




# Technical & Clinical Milestones

DENTAL	Henry Schein Supply & Licensing Agreement Execution	Data read-out from the FDA study	FDA Submission	FDA Clearance		
ORTHOPAEDIC	Master Partnership Agreement Execution	Supply and Licensing Agreement Execution	FDA Submission	FDA Clearance		
ONCOLOGY	FDA Pre-submission/Regulatory Pathway Defined	Tutelix First In Human Cohort 1 Read-out	Quality & Supply Agreement Execution	US/AU Capital Raise	Tutelix Primary End Point for Cohort 2	Pivotal Clinical Trial Initiation
OPHTHALMIC	BioOptix Licensing Agreement	Strategic Global Partnership	US / AU Capital Raise	Preclinical Data Read-out	FDA Pre-submission & Regulatory Pathway	
SURGICAL SITE MGMT	Cohort 2 Commenced	Year 1 Follow up for Cohort 1 results published	TetraDerm Cohort 3 Initiation (Major Surgeries)	FDA Pre-submission & Regulatory Pathway	Primary End-point Cohort 2	
OPERATIONS	IGP Grant	ISO13485 surveillance Audit	New Facility Signed and production begins	Board Restructure	MDSAP Stage 1 Audit	


FY26

FY27

Initiation and successful progression of prostate spacer trial, 15 patients treated with solid indications of performance.



Progression of TetraDerm clinical trial and achieving 1 year follow up data from the cohort 1 of the trial with indications of efficacy.



FDA studies progressing as planned, 100% pass rate for all in vivo implantations safety and performance studies.



# Relentless Operational Execution

DENTAL	<div style="display: flex; justify-content: space-around; align-items: center;"> <span>✓</span> <span>✓</span> </div> <p>Henry Schein Supply &amp; Licensing Agreement Execution    Data read-out from the FDA study    FDA Submission    FDA Clearance</p>
ORTHOPAEDIC	<p>Master Partnership Agreement Execution    Supply and Licensing Agreement Execution    FDA Submission    FDA Clearance</p>
ONCOLOGY	<div style="display: flex; justify-content: space-around; align-items: center;"> <span>✓</span> <span>✓</span> <span>✓</span> <span>✓</span> </div> <p>FDA Pre-submission/Regulatory Pathway Defined    Tutelix First In Human Cohort 1 Read-out    Quality &amp; Supply Agreement Execution    US/AU Capital Raise    Tutelix Primary End Point for Cohort 2    Pivotal Clinical Trial Initiation</p>
OPHTHALMIC	<div style="display: flex; justify-content: space-around; align-items: center;"> <span>✓</span> <span>✓</span> <span>✓</span> </div> <p>BioOptix Licensing Agreement    Strategic Global Partnership    US / AU Capital Raise    Preclinical Data Read-out    FDA Pre-submission &amp; Regulatory Pathway</p>
SURGICAL SITE MGMT	<div style="display: flex; justify-content: space-around; align-items: center;"> <span>✓</span> <span>✓</span> <span>✓</span> </div> <p>Cohort 2 Commenced    Year 1 Follow up for Cohort 1 results published    TetraDerm Cohort 3 Initiation (Major Surgeries)    FDA Pre-submission &amp; Regulatory Pathway    Primary End-point Cohort 2</p>
OPERATIONS	<div style="display: flex; justify-content: space-around; align-items: center;"> <span>✓</span> <span>✓</span> <span>✓</span> <span>✓</span> </div> <p>IGP Grant    ISO13485 surveillance Audit    New Facility Signed and production begins    Board Restructure    MDSAP Stage 1 Audit</p>

FY26

FY27

- Australian Federal Government industry grant, A\$3.3m to co-fund the planned development activities.

- Peter Gray (Co-Founder of Zip) joined the board of directors further strengthening the board to navigate highly regulated global market.
- Completed and successfully passed ISO13485 surveillance audit with construction initiated in the new site for 10X expansion.
- On-budget delivery of milestones and cash on hand A\$19.2m (from A\$25m raised in IPO and A\$9m from pre-IPO).
- Ongoing and meaningful disclosures to the market:

<b>15</b>	<b>8</b>	<b>3</b>	<b>4</b>
Total Reports and Market Updates	Technical and Commercial Updates	Clinical trial updates and news	Partnership and commercial validation

# Not simply a science experiment. Tetramatrix™ provides real world economics.

	Bone Regeneration	Tissue Spacing	Tissue Healing
<b>TAM</b>	<b>US\$3.4bn</b>	<b>US\$1.3bn</b>	<b>US\$2.1bn</b>
<b>Payer</b>	<b>Patient out-of-pocket</b>	<b>Reimbursed (US)</b>	<b>Patient out-of-pocket</b>
<b>Expected GM<sup>1</sup> for Partner</b>	<b>70-80%</b>	<b>~80-90%</b>	<b>~70-80%</b>
<b>Expected GM for Tetratherix</b>	<b>60-70%</b>	<b>~75-85%</b>	<b>~60-70%</b>

We verify the final end user pricing and the gross margin targets for our strategic partners before progressing

1. Weighted Blended Standard Gross Margin

## Advanced manufacturing and operations

We have established advanced manufacturing in Sydney. To meet growing demand, a new lease agreement has been executed and the new facility is planned to be commissioned in CY26, with a modular design to allow us to quickly scale as needed.

Our manufacturing process is:

### Highly Scalable with supply chain security



- Our manufacturing process is **designed in a 'POD' framework whereby every POD can operate independently**
- The POD has a footprint of **200 sqm**, and can be replicated multiple times without our facility floorspace
- Allows multiple X increases in the production capacity in a **fast and controlled manner**

### De-risked





- We have previously **increased our production yield per batch from laboratory scale (10 g per batch) to a commercial scale (1.2kg)** through multiple cycles of process optimisation and scale up
- The production process is not labour-intensive and requires only off-the-shelf equipment
- All raw materials are **catalogue products and easily accessible** from multiple suppliers, de-risking any supply chain risk
- A new, larger site in Alexandria, Sydney has been identified **with the lease now executed and signed**

### Manufacturing POD



# The New Tetratherix HQ and Manufacturing campus construction on track

We have executed a lease agreement (10 + 5 Years) and have secured relevant approval to start construction at the site. The project is on track to move the headquarters to the new site in FY26 and the first formal production in FY27.



# TTX continues to evolve and plans to relentlessly execute into FY27 and beyond

	FY2026	Present	FY2027	H2FY2027
DENTAL	HENRY SCHEIN®	✓ Data read-out from the FDA study	FDA Clearance	First Final Product Dispatch to HS Market Seeding for Portfolio Expansion
ORTHOPAEDIC		✓ Data read-out from the FDA study	FDA Clearance	Supply and Licensing Agreement Execution First Final Product Dispatch to US Partner
ONCOLOGY	✓ FDA QSub/ Regulatory Pathway Defined	✓ Tutelix First In Human Cohort 1 Read-out	✓ Tutelix Pivotal Trial Initiation Australia	Portfolio Expansion IDE Approval from FDA for the US Arm of the Pivotal
OPHTHALMIC	✓ BioOptix Licensing Agreement	✓ Alcon	✓ US / AU Capital Raise Preclinical Data Read-out	Interim Technical Reporting with Alcon FDA Pre-submission & Regulatory Pathway
SURGICAL SITE MGMT	✓ Cohort 2 Commenced	✓ Year 1 Follow up for Cohort 1 results published	✓ Initiation Cohort 3 TetraDerm Cohort 3 Initiation (Major Surgeries)	Primary End-point Cohort 2 Year 1 Data-readout from Cohort 2
OPERATIONS	✓ IGP Grant	✓ New Facility Signed and ISO Surveillance	✓ Board Restructure	MDSAP Stage 1 Audit MDSAP Stage 2 Audit The New Site Head Quarter Opening
PRECISION MEDICINE		✓ superpower	✓ First License Revenue	First Polymer Dispatch (STEPP) STEPP Sale Revenue GLP-1 Data Point 1



# APPENDIX A

# Bone Regeneration – Dental & Orthopaedic



A universal enabling solution to simplify complex oral, dental and orthopaedic procedures


## Tegenix | Dental Bone Graft

### Partners



### Key Dates From the Prospectus

Supply Agreement in FY26  
FDA Clearance in FY26  
Market Launch in FY26 in the US




## TegenEOS | Orthopaedic Bone Graft

### Partners

Currently Under Due Diligence  
with multiple key players

### Key Dates From the Prospectus

Supply Agreement in FY26  
FDA Clearance in FY26  
Market Launch in FY27 in the US




# Tegenix | Dental Bone Graft



On-track commercial launch in FY27 as outlined in the prospectus

Commercial launch of Tegenix is progressed as planned. Global HS as well as the Australian arm are engaged and multiple strategies in place to maximise in market success of the product.

**Tegenix**




**On-track for commercial launch in FY27 as outlined in the prospectus**

---

**Strategic pivot in partnership assessment and still on-track for commercial launch in FY27 as outlined in the prospectus**

## **Strategic Realignment - Prioritising Highest-Return Partnerships**

One of our leading potential ortho partners recently made a strategic shift in product and corporate strategy. This shift meant our long term ortho stability may have been challenging (specifically in the US shift to day-surgery clinics) which would have increased integration complexity and execution risk over the long term. As such, we have deliberately chosen to refocus our due diligence efforts on 2 other leading ortho partners - the advantage of our partnership model.




Two partners now in late stage due diligence

- Partner A: Global market leader with extremely strong enterprise channels and strong revenue growth (in a flat market), offset by legacy integration complexity.
- Partner B: High-growth global scaler with flexible commercial terms and co-innovation upside, offset by execution risk if priorities shift.

Either partner materially strengthens the Tetratherix portfolio and we continue to progress the discussions for final decisions on track for CY26.

## Safe & easy to use solution for more effective & simpler spacing in radiation oncology

Tutelix™ is intended for use as a spacer to reduce side effects to surrounding tissue during radiation therapy to treat prostate cancer. It is easily injected and is gradually resorbed by the body and excreted over time (12 weeks) without harm to any internal organs



### Key features

#### Procedure Optionality

- 1 A water-based solution makes the product amenable to single injection after hydrodissection OR as multiple gradual injections, two commonly used techniques.


#### Simple to adjust (+/- volume)



- 2 Activated organically by body temperature, the solution transitions into a hydrogel. The hydrogel is smooth, flowable and can be immediately reversed with cold-saline. The hydrogel breaks down to non-toxic components and bioresorbs within 3 to 6 months completely.



#### Visible to physicians under both CT-scan and ultrasound


- 3 In contrast to incumbent products, the product is visible under ultrasound during administration and under Computed Tomography without enhancement which allows for a safer, simpler, more accurate and cost-effective outcome when delivering radiotherapy.

Tutelix progressed first in human clinical trial with promising results and completed a priced round of funding from AU and US investors




- 


During the administration process and product gelation, high visibility of prostate via trans rectal ultrasound (TRUS) was maintained.
- 


Spacers retained their structure in all patients and, to date, excellent product stability has been achieved post-implantation throughout the radiotherapy delivery.
- 


**ZERO** Reported Adverse Events from any of the patients treated to date. Multiple patients reach 6 months follow up time point.



# TetraDerm | Tissue Healing

## The world's first intraoperative scar prevention solution

TetraDerm is the only flowable matrix that can be used intraoperatively to provide an internal cushioning effect to physically decrease mechanical tension and dead space, therefore reducing scar formation after any surgery, such as surgical reconstruction, arthroplasty and caesarean procedures




### Key features

- 1 Easy to apply and able to be used intraoperatively**  
 A flowable dermal matrix that forms a uniform hydrogel within dermal layers without the need for any external stimuli, such as light or chemical reaction- gelation is triggered by physiological temperature.
- 2 Superior efficacy in tissue remodelling and wound closure**  
 The mimetic of the hydrogel allows biological integration of the hydrogel within the host tissue and provides a physical scaffold for cellular regeneration and skin remodelling.
- 3 Decreases myofibroblast activity and scar formation**  
 Mechanical tension is the driving force known to increase myofibroblast activity and consequently scar formation. The matrix provides an internal cushioning effect to reduce mechanical tension and dead space, thus preventing scar formation.

# TetraDerm | Early Clinical Findings

## Vancouver Scar Scale (VSS) score of < 2 at all time points

All measurements for all patients were very low (minimal scarring) at all time points. The important time points are 6 weeks for acute response and long term stable responses at 12 months displayed minimal scarring at the site.



## Safety measures that confirms the overall mode of action for TetraDerm

Follow-up	VSS Parameters				Total Average
	Vascularity (0-3)	Pigmentation (0-2)	Pliability (0-5)	Height (0-3)	
Week 6	0.1 ± 0.35	0	0.4 ± 0.5	0.4 ± 0.7	0.9 ± 1.1
Month 3	0.1 ± 0.38	0	0.4 ± 1.3	0.4 ± 0.8	1.8 ± 1.7
Month 6	0.8 ± 0.46	0	0.3 ± 1.0	0.3 ± 0.7	1.6 ± 2.0
Month 12	0.4 ± 0.52	0	0.3 ± 1.1	0.3 ± 0.7	1.1 ± 2.1

**70** Oldest patient treated in the trial with VSS of <1 at all time points  
**years of age**

**9** relatively large wounds with no healing issues  
**cm wound length**

**0** No reports of seroma formation in any of the treated wounds  
**seroma formation**

**0** No reports of inflammation from 2 weeks onwards in any of the patients  
**inflammation**



# STEPP – Tetratherix's enabling vehicle for novel delivery of compounds


The STEPP project has been in stealth mode and under deep development for more than 5 years, including global R&D studies with several big pharma partners.

# Nasal Delivery of the compounds that are all central to the biggest shift in healthcare of our lifetimes

## GLP-1

### A fat lot of trouble


Global obesity-drug sales, \$bn



\*At August 2025  
Source: Bloomberg Intelligence

## Peptides


Interest over time  
United States · Past 5 years



## Hormones

### Estradiol Prescriptions in US

Usage to treat perimenopause and menopause has skyrocketed




Source: Symphony Health data compiled by Bloomberg Intelligence

Bloomberg

# STEPP | Mode of Action for STEPP Drug Delivery

## The Tetramatrix™ platform's STEPP - the enabling vehicle for novel delivery of compounds

The polymer system is negatively charged and the presence of hydrophilic + hydrophobic groups within PNPFO create a protective micelle-like layer around biologics.



# STEPP | An Introduction

## Tetramatrix™ platform - vehicle enabling effective nasal delivery of compounds

### 1 Biological


- Our delivery system facilitates **sustained release** of cargo
- STEPP has been shown to **reduce enzymatic** degradation of incorporated cargo in multiple applications
- Allows **unique routes** for systemic delivery

### 2 Physical

- STEPP forms **protective micelles** around incorporated cargo to allow for stability and protection
- STEPP is a **stabilising agent** for the cargo
- STEPP **retains the cargo** at the delivery site

### 3 Commercial

- STEPP is **simple to incorporate** with routine manufacturing
- STEPP is **proprietary** - allowing a unique product offering
- STEPP may allow for 'surprising synergies' and by extension - facilitate **new formulation patents** for off-patent candidates



# STEPP | Physical Adhesion Is a Big Deal

The use of the carrier in different formulations allows direct spray with no nose or throat run off.

The following example is with mRNA/LNP (Global big pharma collaboration), representing a challenging test for nasal delivery and mucosa adhesion.

The image compares two nasal spray formulations on a human head model. The left side, labeled 'Control (No Carrier)', shows a model with a purple spray. A callout box indicates 'Low coverage at the upper regions'. Below, a close-up shows 'Nose runoff instantly after application'. A small inset shows a test tube with 'Collected solution after spray' and 'Nose runoff and product wastage'. A rounded box states '60% product loss'. The right side, labeled 'With Carrier', shows a model with a purple spray. A callout box indicates 'Upper regions coverage' with arrows pointing to the upper nasal cavity. Below, a close-up shows 'No nose dripping'. A text box below states 'Wide coverage and no nose- and throat- runoff with the carrier system.'

**Control (No Carrier)**

Low coverage at the upper regions

The nose and throat runoff affect the reproducibility of the dosage without the carrier system.

Nose runoff instantly after application

Collected solution after spray

Nose runoff and product wastage

**60% product loss**

**With Carrier**

Upper regions coverage

No nose dripping

Wide coverage and no nose- and throat- runoff with the carrier system.


# STEPP | Mode of Action for STEPP Drug Delivery

## STEPP delivers cargo and maintains activity of different cargos before & after administration

Different in vitro and in vivo preclinical studies have confirmed the potential of the technology to deliver different compounds. STEPP controls the release of cargo and allows both systemic and direct-to-brain delivery of different actives.


- 1**

**Insulin/GLP-1**




- Confirmation of stability
  - Confirmation of sustained release
  - Animal study to show delivery
  
- 2**

**mRNA/LNP**




- Confirmation of stability
  - Confirmation of sustained release
  - Confirmation of biological activity post release
  
- 3**

**Analgesics & Antibiotics**




- Confirmation of stability
  - Confirmation of sustained release
  - Confirmation of in vitro activity post release



Controlled release of active cargos (GLP-1 etc) in the presence of the carrier. Free cargo displayed a burst release, whereas with 25 mg/ml (TP025+) and 35 mg/ml (TP035+) of PNPFO, the burst release is prevented.

The presence of the carrier system prevent the degradation of the cargo in mucosa via enzymes. These results suggest that the carrier can increase the bioavailability of GLP-1 or other actives via nasal delivery.



# Continuous intelligence: real-world evidence acquisition at the biological frontier



## The Partner

**Pioneers of 'Pharma 2.0':** Superpower is a sophisticated US-based precision health company that moves beyond traditional reactive medicine by utilising an AI-driven 'Test, Prescribe, Optimise' model.

**Data-Driven Patient Care:** Their platform integrates comprehensive biomarker tracking - including blood panels and metabolic screening - to proactively identify health issues and generate personalised protocols that combine pharmaceuticals with lifestyle interventions.

**Strategic Market Access:** The partnership utilises an agile 'compounding-first' model, allowing Tetratherix to start collecting real world evidence in the US GLP-1 and peptide markets immediately under existing regulatory frameworks.

**Strong Financial & Consumer Backing:** Superpower is a highly capitalised partner backed by US VC and high profile individuals. The health platform currently has a significant waitlist of over 200,000 people.

## The Agreement

**Exclusive R&D Agreement:** Tetratherix will receive an exclusive licensing fee for the use of its technology in the R&D fields of nasal drug delivery and the subcutaneous delivery of select compounds. This fee is structured as an annual payment of US\$3m payable on renewal by Superpower for up to 10 years.

**Ongoing Polymer Sales:** Beyond licensing, the company will also generate revenue through the sale of the Tetramatrix™ polymer. As Superpower scales its customised product offerings, Tetratherix will act as the primary supplier of this essential biostealth carrier.

**Expedited Pathway to Revenue:** This allows Tetratherix to divert from the traditional, multi-year pharmaceutical development cycles and generate real world demand and an immediate channel to commercialise assets like nasal GLP-1s - generating revenue in FY26.

**Real-World Evidence Generation:** The partnership serves as a high-scale, revenue-generating pilot that provides direct access to real-world use evidence by gathering patient insights on efficacy and tolerance.

## The Opportunity

**Unprecedented Market Scale:** The global market for GLP-1 agonists is currently the fastest-growing sector in pharmaceutical history, projected to exceed US\$100b by 2030. This opportunity extends into the broader peptide and hormone replacement therapy markets, where the shift toward quality of life treatments is driving a wave of demand.

**High-Value Comparable Benchmarks:** The industry is currently in a 'delivery leadership' arms race, evidenced by multi-billion dollar acquisitions of carrier technologies. Notable benchmarks include Novo Nordisk's US\$1.8b acquisition of Emisphere for its SNAC oral delivery technology and Pfizer's recent investment in Metsera for its HALO delivery system.

**The Delivery Holy Grail:** While the efficacy of our targets are well-established, the industry's primary hurdle has shifted from the 'active ingredient' to the 'delivery system'. Nasal delivery is considered the holy grail because it offers the high efficacy of an injection with the frictionless convenience of a spray, potentially capturing the >15% of patients who currently opt out of treatment due to needle fatigue or phobia.



# APPENDIX B

## Key Risks



This section discusses some of the key risks associated with an investment in Tetratherix, which may affect the value of Tetratherix shares. The risks set out below are not listed in order of importance and do not constitute an exhaustive list of all risks involved with an investment in Tetratherix. There is no guarantee that Tetratherix will achieve its stated objectives or that any forward-looking statements or forecasts of Tetratherix will eventuate. Before investing in Tetratherix, you should be aware that an investment in Tetratherix has a number of risks, some of which are specific to Tetratherix and some of which relate to listed securities generally, and many of which are beyond the control of Tetratherix. If any of these risks eventuate, they could have a material adverse effect on Tetratherix's business, financial condition, share price, operating and financial performance and return to shareholders. Before investing in Tetratherix, you should consider whether this investment is suitable for you. Potential investors should carefully review publicly available information on Tetratherix, carefully consider their personal circumstances (including the ability to lose all or a portion of their investment) and consult their professional advisers before making an investment decision. Many of the risks highlighted in this section may be heightened due to the current economic climate and the current and potential future impact of geopolitical tensions. Additional risks and uncertainties that Tetratherix is unaware of, or that it currently considers to be immaterial, may also become important factors that adversely affect Tetratherix's operating and financial performance.

### Early-stage risk

Tetratherix remains pre-revenue and is subject to risks common to early-stage companies, including increasing market share and brand recognition, developing its product pipeline, competition risks and satisfying regulatory requirements imposed on Tetratherix and its products. No assurance can be given that Tetratherix will achieve commercial viability through revenue generated from its flagship Tetramatrix™ platform technology, its derivative products or other products in development (currently or in future). Until Tetratherix is able to realise value from its products, it is likely to incur operational losses.

### Uncertainty of future revenue and profitability

Future sales of products including but not limited to Tetramatrix™ (including any products derived from it) by Tetratherix and Tetratherix's profitability are contingent on, amongst other things, Tetratherix's ability to enter into appropriate partner arrangements, being able to maintain the anticipated process for products being developed, as well as certainty of supply, being able to set favourable prices for products sold, realising market demand for Tetratherix's products and the general economic conditions. Consequently, Tetratherix cannot provide any guarantee that future sales targets will be achieved, or if achieved, that Tetratherix will be profitable.

### Future capital requirements

Tetratherix may require ongoing funding to fund operational costs and to achieve its stated growth plans. There can be no certainty that Tetratherix can raise the necessary funds.

Any equity financing may be dilutive to shareholders and may be undertaken at lower prices than the then market price. Debt financing, if available, may involve restrictive covenants which limit Tetratherix's operations and business strategy.

Loss of key management personnel

The successful operation of Tetratherix in part relies on its ability to attract and retain experienced and high performing key management personnel, in particular those with relevant scientific experience. The loss of any key management or other personnel, or inability to attract additional skilled individuals to key management roles, may adversely affect Tetratherix's ability to develop and implement its business strategies.

### Access to sufficient manufacturing capacity

Tetratherix's growth plans are dependent on access to sufficient manufacturing capacity to meet the demand of future sales, and the costs of inputs and manufacturing operations being appropriate. Challenges in respect of any of the above could adversely impact Tetratherix's supply chain or cost of goods sold and require Tetratherix to source and engage new suppliers in accordance with the quality and regulatory standards for the sector.

### Regulatory risk

Tetratherix operates and intends to operate in regulated industries including medical devices in Australia and internationally (notably the United States). Tetratherix must obtain approval from the regulatory body in the jurisdictions in which it intends to operate in order to legally supply its products. The failure of Tetratherix to obtain the relevant approvals and comply with the laws and regulations in the jurisdictions in which it intends to operate, could result in the loss of access to those and other markets. Compliance with government regulation may also involve additional fees and costs. Changes to these laws and regulations (including interpretation and enforcement), or the failure by Tetratherix to remain current with those changes, could adversely affect Tetratherix's business and financial performance. Tetratherix's Precision Medicine franchise, including its partnership with Superpower Health for the supply of STEPP for use in compounding nasal spray products, relies on the continued availability of compounding exemptions under FDA regulations (Section 503A/B). Tetratherix's commercial pathway is predicated on the intranasal dosage form constituting a significant clinical difference from commercially available injectable and oral products, thereby satisfying the "clinical need" exemption that permits compounding. If the FDA was to determine that the nasal format does not satisfy the clinical necessity exemption, or if it categorically restricted compounding active pharmaceutical ingredients regardless of dosage form, there is a risk that Tetratherix's revenue opportunity through the Superpower Health partnership could be negatively impacted. The FDA has announced its intent to take enforcement actions to restrict the use of GLP-1 active pharmaceutical ingredients in non-FDA approved compounded drugs, particularly those being mass-marketed. The Superpower Health partnership mitigates this risk as Tetratherix's role is to operate as a supplier of bulk excipient (STEPP) rather than as a compounder or dispenser of the final drug product, and Superpower Health operates under a prescription-based model (1-to-1 doctor-patient relationship). If the FDA launched an enforcement action targeting compounding direct prescription pharmacies or intranasal GLP-1 compounding generally, there is a risk that this could impair the potential commercial pathway for Tetratherix's partnership with Superpower Health and its future revenue opportunities.

### Ownership and protection of intellectual property

The business of Tetratherix depends on its ability to commercially exploit its intellectual property. Tetratherix relies on laws relating to patents, trade secrets, copyright and trade marks to assist in protecting its proprietary rights. There is a risk that unauthorised use or copying of the secure documentation, business data or intellectual property will occur.

Tetratherix may not be able to detect the unauthorised use of its intellectual property rights in all instances. A breach of Tetratherix's intellectual property may result in the need to commence legal actions, which could be costly and time consuming. A failure or inability to protect Tetratherix's intellectual property rights could have an adverse impact on operating and financial performance. There is always a risk that third parties could claim involvement in scientific discoveries or that Company is infringing the intellectual property of a third party. Any resulting claims and disputes could adversely affect Tetratherix, and due to the complex nature of intellectual property, could be drawn out and expensive. If a claim is successful Tetratherix may be required to pay damages or be restrained from further developing or commercialising its products.

### Dilution risk

Existing shareholders who do not participate in the Offer will be diluted as a result of the issue of new shares. In the future, Tetratherix may decide to issue additional shares to raise funds and shareholders may be diluted as a result.

### Liquidity risk

There is no guarantee of an active market for Tetratherix's shares or that the price of Tetratherix's shares will increase. Shareholders who wish to sell their Offer shares may be unable to do so at an acceptable price, or at all, if insufficient liquidity exists in the market. Therefore, changes in the prevailing market price of Tetratherix's shares may result in a loss of money invested for shareholders.

### Patents and trademarks

Tetratherix currently holds a number of registered patents, has a number of pending patent applications and a number of registered trademarks. There is a risk that the pending patent applications may not be granted or may change in scope when subject to examination. Tetratherix's success in part depends on its ability to obtain these additional patents, and trademarks, maintain trade secret protection and operate without infringing the proprietary rights of third parties. If these additional patents are not granted, or if granted only for limited claims, Tetratherix's intellectual property may not be adequately protected and may be able to be copied, reproduced or otherwise circumvented by third parties, which may adversely impact its ability to achieve its objectives or generate revenue and other returns.

### Risk of delay and continuity of operations

Tetratherix may experience delays in achieving a number of critical milestones, including completion or trials, obtaining regulatory approvals, supply chain disruptions, manufacturing, product launches and sales. Any material delay may adversely impact Tetratherix, including the timing of any revenue or sales payments. Tetratherix may also experience business continuity challenges from extreme events. As with most businesses, Tetratherix is reliant on IT systems in its day-to-day operations. An inability to operate such systems (e.g. from a computer virus or other cyber-attacks or from a physical event at its offices, laboratory or manufacturing facility) would impact the business.

### Contract risk

The operations of Tetratherix will require the involvement of a number of third parties, including suppliers, contractors, and customers. With respect to these third parties, and despite applying best practice in terms of pre-contracting due diligence, Tetratherix is unable to avoid the risk of financial failure, performance failure or default by a contractor or customer.

### Results of studies

Tetratherix has already undertaken a number of performance studies in order to validate the effectiveness of its current product lines. There is no guarantee that future product performance will align with the expected performance achieved in studies to date. Future products testing will be required for future regulatory clearance and approval. This may result in additional cost and time to deliver products to market.

### Research and development claims

As the developer of biomaterials Tetratherix has previously claimed material tax offsets in respect of its research and development activities. These claims have been self-assessed but are subject to comprehensive criteria and may be subject to future audit and adjustment or claw-back.

### Product risks and liability

As Tetratherix develops and markets new products based on its Tetramatrix™ platform technology and obtains the relevant regulatory approvals, there is no assurance that unforeseen adverse events of manufacturing defects will not arise. Such events or defects could expose Tetratherix to product liability claims, litigation or withdrawal of regulatory approvals. They could also result in damages being awarded against Tetratherix, a requirement for further investment in improved manufacturing processes or withdrawal of products from market. In such event, Tetratherix's liability may exceed its insurance coverage.

### Market acceptance and competitor risk

Market acceptance depends on numerous factors, including our partners' ability to convince potential consumers and agents of the attractiveness of Tetratherix's products and its ability to manufacture those products to a sufficient quality and quantity to meet commercial demand at an acceptance cost. There is a risk that Tetratherix's partners may not gain widespread market acceptance and retention as anticipated, which may adversely affect Tetratherix's financial performance. Notwithstanding the number of participants in a market, there is always a risk that there will be new entrants into the market and that existing competitors will introduce new products or technologies that are superior or more favourable with the market. Competition has the potential to impact Tetratherix's business and market share including but not limited to a competitor bringing to market a FDA-approved intranasal delivery system which may narrow the regulatory basis for compounding.

## Key Risks continued



### TAM assumptions

The TAM figures presented in this Presentation are based on broad industry estimates and may not accurately reflect the specific markets in which Tetratherix has enforceable patent protection or commercial rights. While these TAM figures provide insight into the potential scale of the industry, they may not necessarily correspond to Tetratherix's current or near-term addressable markets. Patent protection and regulatory approvals may limit Tetratherix's ability to operate or commercialise its products developed under the Tetramatrix™ platform technology in certain jurisdictions, thereby reducing the size of the actual addressable market. As a result, investors should not rely solely on TAM figures when evaluating Tetratherix's growth potential or future financial performance.

### Failure to realise benefits from product research and development

An important aspect of Tetratherix's business is to continually invest in innovation and produce development opportunities. Tetratherix may not realise benefits from investments in research and development for several years, or in some cases, may not realise any benefits at all. Tetratherix makes assumptions about the expected future benefits generated by investments in research and development and the expected timeframe in which the benefits will be realised. These assumptions are subject to change and involve both known and unknown risks that are beyond Tetratherix's control. Any change to the assumptions that Tetratherix has made about the development of a certain product may have an adverse impact on Tetratherix's ability to realise a benefit from the investment in the development of that product.

### Market conditions

The market price of the shares can fall as well as rise and may be subject to varied and unpredictable influences on the market for equities in health science stocks in particular. Further, share market conditions may affect the value of Tetratherix's quoted shares regardless of Tetratherix's operating performance. Share market conditions are affected by many factors such as: general economic outlook; interest rates and inflation rates; currency fluctuations; changes in investor sentiment; the demand for, and supply of, capital; and terrorism or other hostilities. Neither Tetratherix nor the Directors warrant the future performance of Tetratherix or any return on an investment in Tetratherix.

### Foreign currency and exchange rate fluctuations

Tetratherix transacts in various currencies other than the Australian dollar reporting currency, including United States Dollar and Euro. Tetratherix has not historically hedged its foreign currency exposure and as a result earnings are exposed to the net impact of movements in foreign exchange on sales, employee expenses and purchases in foreign currencies in which the transaction occurs.

### Trade and trade restrictions

Tetratherix, and its current and future business model, relies on the export of its products to various international markets and is therefore subject to risks associated with changes in trade policies and the imposition of trade restrictions, including but not limited to: tariffs; quotas; and other non-tariff barriers. The introduction of new tariffs or trade restrictions, or the modification or withdrawal of existing trade agreements by governments in jurisdictions where Tetratherix exports, could materially impact Tetratherix's product pricing, competitiveness, supply chain and profitability. Additionally, retaliatory measures and evolving geopolitical tensions may further restrict market access or increase costs, adversely affecting Tetratherix's financial performance and growth prospects.

### Cyber Security

Given Tetratherix's dependence on information technology systems and infrastructure used in the manufacture of the flagship Tetramatrix™ platform technology and its derivative products, Tetratherix is vulnerable to cyber-attacks, ransomware attacks, computer viruses or data breaches. This is particularly the case given the increasing frequency and sophistication of attacks experienced by other businesses globally. Such risks may also result directly or indirectly from a security breach of one of Tetratherix's third-party service providers. Tetratherix relies on its third-party service providers' cyber resilience capabilities. However, third-party service provider counter measures may not be sufficient to detect or prevent all unauthorised and/or malicious acts. Further, Tetratherix's use of prominent third-party providers may increase Tetratherix's exposure to potential cyber-attacks (and hence interruptions to the manufacturing process) due to such third-party service providers being targeted by cyber criminals because of their size of client base and brand prominence. A security breach or cyber-attack could result in business disruption and cost through the unavailability of core business systems. Disclosure of sensitive business information is also a risk. Other consequences could include legal or regulatory liability (or increased regulatory scrutiny) and Tetratherix may incur significant costs to investigate and rectify the incidents, including identifying system vulnerabilities or introducing additional safeguards to minimise the risk of future events. Any of these cyber security issues could therefore have a material adverse impact on the operating performance and financial position of Tetratherix and could cause reputational harm.

### Force majeure

Events may occur within or outside the markets in which Tetratherix operates that could impact upon the global or Australian economies and the operations of Tetratherix. These events include acts of terrorism, outbreaks of international hostilities, fires, pandemics, floods, earthquakes, labour strikes, civil wars, natural disasters, outbreaks of disease, and other man-made or natural events or occurrences that can have an adverse effect on Tetratherix's ability to conduct business.

### Litigation risks

Tetratherix is exposed to possible litigation risks including occupational health and safety claims, employee claims, and product liability claims. The compounding market which Tetratherix will be supplying to under its Precision Medicine franchise is subject to active litigation from major pharmaceutical companies. While Tetratherix believes that its nasal spray format represents a distinct dosage form that is legally differentiated from injectable and oral "copycat" products that have been targeted in recent litigation, there is no assurance that Tetratherix and Superpower Health's partnership will not be disrupted by legal action that could result in legal costs, management distraction, reputational harm, and disruption to the commercial partnership. Further, Tetratherix may in the ordinary course of business become involved in litigation and disputes, for example with service providers, customers or third parties infringing Tetratherix's intellectual property rights. Any such claim or dispute if proven, may impact adversely on Tetratherix's operations, financial performance, and financial position.

### Changes in taxation laws and policies

Tax laws are in a continual state of change which may affect Tetratherix and its shareholders. Changes to rules relating to research and development tax incentives, including changes to the eligibility requirements or refund levels could adversely affect Tetratherix's financial performance and cash flows. Research and development tax incentives, concessions and grants are subject to policy review and discretion and there can be no guarantee that any concession or grant will be awarded to Tetratherix. Changes to tax laws may adversely affect Tetratherix's financial performance and/or the returns achieved by investors. Future dividends paid to certain investors may not be recognised as frankable by the ATO.

### Taxation

There may be tax implications arising from ownership of the shares, the receipt of franked and unfranked dividends (if any) from Tetratherix, the receipt of any returns of capital and the disposal of the shares. The acquisition and disposal of shares will have tax consequences, which will differ depending on the individual financial affairs of each investor. All potential investors in Tetratherix are urged to obtain independent financial advice about the consequences of acquiring shares from a taxation point of view and generally. To the maximum extent permitted by law, Tetratherix, its officers, and each of their respective advisers accept no liability and responsibility with respect to the taxation consequences of applying for shares under the Offer, or any taxation implications or penalties incurred by investors.

### Unforeseen expenditure risk

Expenditure may need to be incurred that has not been taken into account by Tetratherix. Although Tetratherix is not aware of any such additional expenditure requirements, if such expenditure is subsequently incurred, this may adversely affect the expenditure proposals of Tetratherix.

### Changes to legislation or regulations

Tetratherix may be affected by changes to laws and regulations in Australia or jurisdictions in which its products are distributed. Such changes could have adverse impacts on Tetratherix from a financial and operational perspective.



# APPENDIX C

## International Offer Restrictions



This Presentation does not constitute an offer of New Shares of Tetratherix in any jurisdiction in which it would be unlawful. In particular, this Presentation may not be distributed to any person, and the shares may not be offered or sold, in any country outside Australia or New Zealand except to the extent permitted below. This document does not constitute an offer of new ordinary shares ("New Shares") of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold, in any country outside Australia except to the extent permitted below.

### Canada (Alberta, British Columbia, Ontario and Quebec provinces)

This document constitutes an offering of New Shares only in the Provinces of Alberta, British Columbia, Ontario and Quebec (the "Provinces"), only to persons to whom New Shares may be lawfully distributed in the Provinces, and only by persons permitted to sell such securities. This document is not a prospectus, an advertisement or a public offering of securities in the Provinces. This document may only be distributed in the Provinces to investors that are both (i) "accredited investors" (as defined in National Instrument 45-106 – Prospectus Exemptions) and (ii) "permitted clients" (as defined in National Instrument 31-103 – Registration Requirements, Exemptions and Ongoing Registrant Obligations). No securities commission or authority in the Provinces has reviewed or in any way passed upon this document, the merits of the New Shares or the offering of the New Shares and any representation to the contrary is an offence. No prospectus has been, or will be, filed in the Provinces with respect to the offering of New Shares or the resale of such securities. Any person in the Provinces lawfully participating in the offer will not receive the information, legal rights or protections that would be afforded had a prospectus been filed and receipted by the securities regulator in the applicable Province. Furthermore, any resale of the New Shares in the Provinces must be made in accordance with applicable Canadian securities laws. While such resale restrictions generally do not apply to a first trade in a security of a foreign, non-Canadian reporting issuer that is made through an exchange or market outside Canada, Canadian purchasers should seek legal advice prior to any resale of the New Shares. The Company as well as its directors and officers may be located outside Canada and, as a result, it may not be possible for purchasers to effect service of process within Canada upon the Company or its directors or officers. All or a substantial portion of the assets of the Company and such persons may be located outside Canada and, as a result, it may not be possible to satisfy a judgment against the Company or such persons in Canada or to enforce a judgment obtained in Canadian courts against the Company or such persons outside Canada. Statutory rights of action for damages and rescission. Securities legislation in certain Provinces may provide a purchaser with remedies for rescission or damages if an offering memorandum contains a misrepresentation, provided the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's Province. A purchaser may refer to any applicable provision of the securities legislation of the purchaser's Province for particulars of these rights or consult with a legal adviser. Certain Canadian income tax considerations. Prospective purchasers of the New Shares should consult their own tax adviser with respect to any taxes payable in connection with the acquisition, holding or disposition of the New Shares as there are Canadian tax implications for investors in the Provinces. Language of documents in Canada. Upon receipt of this document, each investor in Canada hereby confirms that it has expressly requested that all documents evidencing or relating in any way to the sale of the New Shares (including for greater certainty any purchase confirmation or any notice) be drawn up in the English language only. Par la réception de ce document, chaque investisseur canadien confirme par les présentes qu'il a expressément exigé que tous les documents faisant foi ou se rapportant de quelque manière que ce soit à la vente des valeurs mobilières décrites aux présentes (incluant, pour plus de certitude, toute confirmation d'achat ou tout avis) soient rédigés en anglais seulement.

### European Union (excluding Austria)

This document has not been, and will not be, registered with or approved by any securities regulator in the European Union. Accordingly, this document may not be made available, nor may the New Shares be offered for sale, in the European Union except in circumstances that do not require a prospectus under Article 1(4) of Regulation (EU) 2017/1129 of the European Parliament and the Council of the European Union (the "Prospectus Regulation"). In accordance with Article 1(4)(a) of the Prospectus Regulation, an offer of New Shares in the European Union is limited to persons who are "qualified investors" (as defined in Article 2(e) of the Prospectus Regulation).

### Hong Kong

WARNING: This document has not been, and will not be, registered as a prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it been authorised by the Securities and Futures Commission in Hong Kong pursuant to the Securities and Futures Ordinance (Cap. 571) of the Laws of Hong Kong (the "SFO"). Accordingly, this document may not be distributed, and the New Shares may not be offered or sold, in Hong Kong other than to "professional investors" (as defined in the SFO and any rules made under that ordinance). No advertisement, invitation or document relating to the New Shares has been or will be issued, or has been or will be in the possession of any person for the purpose of issue, in Hong Kong or elsewhere that is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to New Shares that are or are intended to be disposed of only to persons outside Hong Kong or only to professional investors. No person allotted New Shares may sell, or offer to sell, such securities in circumstances that amount to an offer to the public in Hong Kong within six months following the date of issue of such securities. The contents of this document have not been reviewed by any Hong Kong regulatory authority. You are advised to exercise caution in relation to the offer. If you are in doubt about any contents of this document, you should obtain independent professional advice.

### New Zealand

This document has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (New Zealand) (the "FMC Act"). The New Shares are not being offered or sold in New Zealand (or allotted with a view to being offered for sale in New Zealand) other than to a person who: (i) is an investment business within the meaning of clause 37 of Schedule 1 of the FMC Act; (ii) meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act; (iii) is large within the meaning of clause 39 of Schedule 1 of the FMC Act; (iv) is a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act; or (v) is an eligible investor within the meaning of clause 41 of Schedule 1 of the FMC Act.

### Norway

This document has not been approved by, or registered with, any Norwegian securities regulator under the Norwegian Securities Trading Act of 29 June 2007 no. 75. Accordingly, this document shall not be deemed to constitute an offer to the public in Norway within the meaning of the Norwegian Securities Trading Act. The New Shares may not be offered or sold, directly or indirectly, in Norway except to "professional clients" (as defined in the Norwegian Securities Trading Act).

### Singapore

This document and any other materials relating to the New Shares have not been, and will not be, lodged or registered as a prospectus in Singapore with the Monetary Authority of Singapore. Accordingly, this document and any other document or materials in connection with the offer or sale, or invitation for subscription or purchase, of New Shares, may not be issued, circulated or distributed, nor may the New Shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore except pursuant to and in accordance with exemptions in Subdivision (4) Division 1, Part 13 of the Securities and Futures Act 2001 of Singapore (the "SFA") or another exemption under the SFA. This document has been given to you on the basis that you are an "institutional investor" or an "accredited investor" (as such terms are defined in the SFA). If you are not such an investor, please return this document immediately. You may not forward or circulate this document to any other person in Singapore. Any offer is not made to you with a view to the New Shares being subsequently offered for sale to any other party in Singapore. On-sale restrictions in Singapore may be applicable to investors who acquire New Shares. As such, investors are advised to acquaint themselves with the SFA provisions relating to resale restrictions in Singapore and comply accordingly.

### Switzerland

The New Shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange or on any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the New Shares constitutes a prospectus or a similar notice, as such terms are understood under art. 35 of the Swiss Financial Services Act or the listing rules of any stock exchange or regulated trading facility in Switzerland. No offering or marketing material relating to the New Shares has been, nor will be, filed with or approved by any Swiss regulatory authority or authorised review body. In particular, this document will not be filed with, and the offer of New Shares will not be supervised by, the Swiss Financial Market Supervisory Authority (FINMA). Neither this document nor any other offering or marketing material relating to the New Shares may be publicly distributed or otherwise made publicly available in Switzerland. The New Shares will only be offered to investors who qualify as "professional clients" (as defined in the Swiss Financial Services Act). This document is personal to the recipient and not for general circulation in Switzerland.

### United Arab Emirates

This document does not constitute a public offer of securities in the United Arab Emirates and the New Shares may not be offered or sold, directly or indirectly, to the public in the UAE. Neither this document nor the New Shares have been approved by the Securities and Commodities Authority ("SCA") or any other authority in the UAE. No marketing of the New Shares has been, or will be, made from within the UAE other than in compliance with the laws of the UAE and no subscription for any securities may be consummated within the UAE. This document may be distributed in the UAE only to "professional investors" (as defined in the SCA Board of Directors' Decision No.13/RM of 2021, as amended). No offer of New Shares will be made to, and no subscription for New Shares will be permitted from, any person in the Abu Dhabi Global Market or the Dubai International Financial Centre.

### United Kingdom

This document has not been delivered for approval to the Financial Conduct Authority in the United Kingdom and no prospectus (within the meaning of Regulation 21 of the Public Offers and Admissions to Trading Regulations 2024 ("POATRs")) has been published or is required to be published in respect of the New Shares. This document is issued on a confidential basis to "qualified investors" (within the meaning of paragraph 2 of Schedule 1 to the POATRs) in the United Kingdom. The New Shares may not be offered or sold in the United Kingdom by means of this document or any other document except pursuant to an exemption from the general prohibition on offers of relevant securities to the public in the United Kingdom. This document should not be distributed, published or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person in the United Kingdom. Any invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended ("FSMA")) received in connection with the offer or sale of the New Shares has been, and only will be, communicated or caused to be communicated in the United Kingdom in circumstances in which section 21(1) of the FSMA does not apply to the Company. In the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 ("FPO"), (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated ("relevant persons"). The investment to which this document relates is available only to relevant persons. Any person who is not a relevant person should not act or rely on this document.

